The Peter Attia Drive Qualy #46 - Rapamycin’s effects on cancer, cardiovascular disease, and neurodegeneration
Oct 23, 2019
The discussion delves into rapamycin's potential to delay cancer progression, emphasizing its significance for longevity. An intriguing comparison is made between rapamycin and other immunosuppressants, shedding light on their complex roles in cancer rates. Additionally, the podcast explores the link between rapamycin, the mTOR pathway, and neurodegeneration, underlining autophagy's importance for brain health. A surprising angle reveals the liver's possible role in appetite regulation, challenging conventional beliefs about brain function.
AI Snips
Chapters
Transcript
Episode notes
Rapamycin and Cancer Treatment
- Rapamycin is not a cytotoxic agent and won't kill cancer cells directly.
- It may impact cancer growth by affecting the immune system and tumor development.
Rapamycin and Cancer Incidence in Transplant Patients
- Studies comparing transplant patients with and without rapamycin show interesting results.
- Rapamycin may mitigate increased cancer risk from immunosuppression by targeting cancer cells directly.
mTOR, Autophagy, and Brain Health
- Autophagy plays a crucial role in brain health, potentially impacting neurodegenerative diseases.
- mTORC1 activity is essential for healthy brain synapses during development, but also needs modulation.